Percutaneous Left Atrial Appendage Occlusion for Patients in Atrial Fibrillation Suboptimal for Warfarin Therapy5-Year Results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study
Peter C. Block, MD*,*,
Steven Burstein, MD ,
Paul N. Casale, MD ,
Paul H. Kramer, MD ,
Paul Teirstein, MD||,
David O. Williams, MD¶,
Mark Reisman, MD#
* Emory University, Atlanta, Georgia
Los Angeles Cardiology Associates, Los Angeles, California
The Heart Group, Lancaster, Pennsylvania
Shawnee Mission Medical Center, Shawnee, Kansas
|| Scripps Memorial Hospital, San Diego, California
¶ The Rhode Island Hospital, Providence, Rhode Island
# Swedish Medical Center, Seattle, Washington
View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Difference Between the Expected Versus Observed Stroke/TIA Rates in the PLAATO U.S. Feasibility Study
The purple bar represents the expected stroke/transient ischemic attack (TIA) rate calculated from the patient population CHADS2 score (6.6%). The actual observed stroke/TIA rate was 3.8% (depicted by the blue bar). PLAATO = Percutaneous Left Atrial Appendage Transcatheter Occlusion.
|
|
View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Kaplan-Meier Analysis of Time to MAE
The table depicts the number of years after the index procedure, the actual number of patients at risk at each year end, the number of events, and the percentage of patients free of major adverse events (MAEs). *12 subjects completed the 5-year follow-up visit prior to early study termination; 17 subjects had a total of 18 MAEs. One subject experienced 2 MAE events. Solid line = product-limit estimate curve; circles = censored objectives. PLAATO = Percutaneous Left Atrial Appendage Transcatheter Occlusion.
|
|
|
